RLYB

Business Context and Reporting Period

Rallybio Corp (RLYB) is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. The filing covers the fiscal year ended December 31, 2024. The company's pipeline centers on two primary clinical programs: RLYB212 (an anti-HPA-1a antibody for preventing fetal and neonatal alloimmune thrombocytopenia, or FNAIT) and RLYB116 (a C5 inhibitor for complement dysregulation diseases). As of December 31, 2024, the company employed 25 full-time staff.

Key Financial Metrics

Note: The company has no commercial product sales. Revenue in 2024 was derived from a collaboration agreement with Johnson & Johnson.

Material Changes vs. Prior Period

• Revenue Generation: The company recorded $0.6 million in revenue in 2024, compared to zero in 2023, driven by the Johnson & Johnson (J&J) Collaboration Agreement and an equity investment from J&J Innovation (JJDC).
• Expense Reduction: Total operating expenses decreased by $17.8 million (22.5%) year-over-year. This was primarily due to a workforce reduction effective March 6, 2024, which eliminated approximately 45% of positions, and decreased costs for RLYB212 and RLYB116 development programs.
• Net Loss Improvement: Net loss narrowed by $16.8 million to $57.8 million, reflecting the reduction in operating expenses.
• Liquidity Position: Cash and marketable securities decreased by approximately $44.4 million, primarily due to operating cash burn and net cash outflows from investing activities (net purchases of securities were offset by maturities).

Guidance, Outlook, and Risks

• Clinical Milestones:
  • RLYB212: A Phase 2 clinical trial in pregnant women is ongoing. The sentinel patient was enrolled in February 2025. The company expects to report second-trimester PK and safety data in Q2 2025 and delivery data in Q3 2025.
  • RLYB116: A confirmatory PK/PD trial is planned for initiation in Q2 2025 to demonstrate improved tolerability and sustained complement inhibition.
• Capital Runway: Management believes existing cash, cash equivalents, and marketable securities ($65.5 million as of Dec 31, 2024) are sufficient to fund operations into the second half of 2026.
• Collaborations:
  • Johnson & Johnson: Entered a collaboration in April 2024 to share data on FNAIT studies. Received $0.5 million upfront and $6.6 million in equity investment.
  • Recursion (formerly Exscientia): Joint venture (REV-I) continues for ENPP1 inhibitor discovery for Hypophosphatasia (HPP).
• Key Risks:
  • Delisting Risk: Received notice from Nasdaq on February 24, 2025, that the stock price fell below the $1.00 minimum bid price requirement. The company has until August 25, 2025, to regain compliance.
  • Financing Needs: The company anticipates continuing to incur significant losses and will require substantial additional capital to complete development and commercialization. Failure to raise capital could force delays or termination of programs.
  • Regulatory Uncertainty: Success depends on obtaining regulatory approvals for RLYB212 and RLYB116, which are in early-stage clinical development.

Investor Verification Checklist

• Stock Price Compliance: Verify if Rallybio has regained compliance with Nasdaq's $1.00 minimum bid price requirement by the August 25, 2025 deadline.
• RLYB212 Phase 2 Data: Monitor the release of second-trimester and delivery data in 2025 to assess the drug's safety and efficacy profile in pregnant women.
• Capital Raising Activity: Track any new equity offerings or debt financings, given the company's cash runway extends only to late 2026 and the need to fund Phase 3 trials.
• Restructuring Impact: Confirm that the 45% workforce reduction has stabilized operating costs and that the remaining team is sufficient to execute the clinical plan.
• Joint Venture Status: Review the financial health and progress of the REV-I joint venture with Recursion, which contributed to the company's net loss.